Clinical trials: Dose Finding Study
Enterotoxigenic E. Coli (ETEC) Infection
ACE527 Safety and Immunogenicity Study
The purpose of this study is to evaluate the safety and immune response to ACE527.
- Trial name
- NCT00901654
- Testing
- ACE527 vaccine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- TD Vaccines A/S
Lymphoma, Neoplasms
A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Lymphoma.
The purpose of this study is to assess the safety of the drug (JNJ-24681585 a drug in development for cancer) in patients with advanced or refractory solid malignancies or lymphoma on the maximum dose that can be tolerated by…
- Trial name
- NCT00677105
- Testing
- JNJ-26481585
- Where
- 6 sites in United Kingdom
- Volunteers
- 92 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Idiopathic Pulmonary Fibrosis
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.
- Trial name
- ELEVATE (NCT05321420)
- Testing
- Pirfenidone, Deupirfenidone
- Where
- 103 sites in United States, Argentina and 12 more
- Volunteers
- 240 people
- Sponsor
- PureTech
Non Small Cell Lung Carcinoma
ZD6474 Phase IIa Dose Finding Multicentre Study
To assess the objective response rates (by RECIST) to ZD6474 100, 200 and 300 mg/day respectively
- Trial name
- NCT00252746
- Testing
- ZD6474 (vandetanib) 100mg, ZD6474 (vandetanib) 200mg, ZD6474 (vandetanib) 300mg
- Where
- 7 sites in Japan
- Volunteers
- 53 people
- Sponsor
- Genzyme, a Sanofi Company
Palmoplantar Pustulosis (PPP)
A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
The primary objective is to provide dose-ranging data for 4 dose regimens of BI 655130 compared to placebo on the primary endpoint of percentage change from baseline in PPP ASI at Week 16.
- Trial name
- NCT04015518
- Testing
- Spesolimab
- Where
- 88 sites in United States, Australia and 13 more
- Volunteers
- 152 people
- Sponsor
- Boehringer Ingelheim
Growth Hormone Disorder, Growth Hormone Deficiency in Children
Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency
This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of once-weekly NNC0195-0092 treatment compared to daily growth hormone treatment (Norditropin® FlexPro®) in growth hormone treatment…
- Trial name
- NCT02616562
- Testing
- somapacitan, Norditropin® FlexPro® pen
- Where
- 89 sites in United States, Austria and 12 more
- Volunteers
- 76 people
- Sponsor
- Novo Nordisk A/S
Prostate Cancer
Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer
The purpose of the trial was to evaluate the safety and efficacy of degarelix when comparing six different doses. The patients participating in the trial were treated with degarelix every month for a year.
- Trial name
- NCT00819156
- Testing
- degarelix
- Where
- 39 sites in Belgium, Germany and 6 more
- Volunteers
- 189 people
- Sponsor
- Ferring Pharmaceuticals
Healthy Subject
Dose Escalating Study of BPI-3016 in Healthy Subjects
This is a randomized, double-blind, placebo-controlled, dose finding study evaluating the safety, pharmacokinetics and pharmacodynamics of subcutaneously injected BPI-3016 in Chinese healthy subjects.
- Trial name
- NCT03188848
- Testing
- BPI-3016
- Where
- China
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Acute Pharyngitis
A Clinical Trial Investigating the Short-term Relief of Symptoms of Acute Pharyngitis by Treatment With Three Different Doses of MYRAMISTIN™ Oromucosal Spray
In this multi-center, randomized, placebo-controlled, double-blind stuy in which patients with acute pharyngitis will receive Myramistin™ / Placebo, which is provided as a spray.
- Trial name
- MIRA1 (NCT04470089)
- Testing
- Myramistin
- Where
- 12 sites in Austria, Germany
- Volunteers
- 170 people
- Sponsor
- Megainpharm GmbH
Non-Small Cell Lung Cancer
Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®
To determine the optimal dose and schedule of Fusilev to prevent or reduce Folotyn-related Grade 3 or higher oral mucositis in patients with Non-Small Cell Lung Cancer.
- Trial name
- NCT01820091
- Testing
- Folotyn, Fusilev
- Sponsor
- Acrotech Biopharma Inc.
Thromboembolism
Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)
The purpose of this study is to find the best possible (optimal) dose (effect versus adverse events) of YM150 to prevent the risk of blood clot formation after scheduled hip replacement surgery.
- Trial name
- NCT00353678
- Testing
- YM150
- Where
- 79 sites in Austria, Bosnia and Herzegovina and 15 more
- Volunteers
- 1,141 people
- Sponsor
- Astellas Pharma Inc
Advanced Solid Tumor
An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).
This open label, dose escalation module will evaluate the safety, tolerability, PK, PD, and preliminary efficacy of PTT-4256 in participants with solid tumours using a combination of accelerated dose titration (ADT) and Bayesian…
- Trial name
- NCT06634849
- Testing
- PTT-4256
- Where
- 5 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Pathios Therapeutics Pty Ltd
Neoplasms, Breast Neoplasms
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
This is a study in adult patients with different types of cancer. The purpose of this study is to find a safe dose of: Xentuzumab in combination with abemaciclib Xentuzumab in combination with abemaciclib and hormonal therapies…
- Trial name
- NCT03099174
- Testing
- Xentuzumab, Abemaciclib, Letrozole
- Where
- 30 sites in United States, Denmark and 5 more
- Volunteers
- 133 people
- Sponsor
- Boehringer Ingelheim
Vasomotor Symptoms
A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women
A randomized, double-blind, placebo-controlled phase 2 clinical study to evaluate the efficacy and safety of HS-10384 in postmenopausal women suffering from vasomotor symptoms.
- Trial name
- NCT06393673
- Testing
- HS-10384 tablet Dose 1, HS-10384 tablet Dose 2
- Where
- China
- Volunteers
- 195 people
- Sponsor
- Hansoh BioMedical R&D Company
Acute Graft Versus Host Disease
Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD
To determine a safe and effective dose of pentostatin in steroid-refractory aGvHD and to identify the minimal effective dose of pentostatin defined as the lowest dose that produces a response in 20% or more of patients while…
- Trial name
- NCT00032773
- Testing
- pentostatin for injection
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Chronic Renal Failure
Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis
To investigate the efficacy, pharmacokinetics, pharmacodynamics, and safety of OPC-41061 in patients with chronic renal failure who are undergoing peritoneal dialysis, using daily urine volume, body weight, and edematous…
- Trial name
- NCT01895322
- Testing
- OPC-41061
- Where
- 6 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Healthy
Dose-finding Study of LFB-R593, A Monoclonal Anti-RhD Antibody, in Healthy RhD Negative Volunteers
This phase II study is designed to demonstrate the ability of LFB-R593 to effectively eliminate exogenously-administered RhD-positive red blood cells from the circulation of an RhD-negative individual, thereby preventing…
- Trial name
- NCT00952575
- Testing
- polyclonal anti-D immunoglobulin, monoclonal anti-D immunoglobulin
- Where
- Germany
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
Plaque Psoriasis
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
- Trial name
- EVERLAST-B (NCT07290569)
- Testing
- ORKA-001
- Where
- 36 sites in United States, Canada and 2 more
- Volunteers
- 160 people
- Sponsor
- Oruka Therapeutics, Inc.
Attention Deficit Hyperactivity Disorder
Dose Finding Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)(174007/P05805/MK-8777-003)
This is a Phase 2 multicenter, randomized, double-blind trial of MK-8777 (Org 26576, SCH 900777) in adult subjects with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT00610441
- Testing
- MK-8777
- Volunteers
- 67 people
- Sponsor
- Merck Sharp & Dohme LLC
Generalized Pustular Psoriasis
A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
This is a study in adolescents and adults with Generalized Pustular Psoriasis (GPP). People between 12 and 75 years old can take part in the study.
- Trial name
- NCT04399837
- Testing
- Spesolimab
- Where
- 72 sites in United States, Argentina and 21 more
- Volunteers
- 123 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.